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Abstract
Background: Low serum paraoxonase (PON) activity is associated with the risk of coronary artery disease, diabetes
and systemic lupus erythematosus (SLE). Our prior studies have shown that the PON1/rs662 (p.Gln192Arg), PON1/
rs854560 (p.Leu55Met), PON3/rs17884563 and PON3/rs740264 SNPs (single nucleotide polymorphisms) significantly
affect serum PON activity. Since PON1, PON2 and PON3 share high degree of structural and functional properties, in
this study, we examined the role of PON2 genetic variation on serum PON activity, risk of SLE and SLE-related
clinical manifestations in a Caucasian case-control sample.
Methods: PON2 SNPs were selected from HapMap and SeattleSNPs databases by including at least one tagSNP
from each bin defined in these resources. A total of nineteen PON2 SNPs were successfully genotyped in 411 SLE
cases and 511 healthy controls using pyrosequencing, restriction fragment length polymorphism (RFLP) or TaqMan
allelic discrimination methods.
Results: Our pair-wise linkage disequilibrium (LD) analysis, using an r
2 cutoff of 0.7, identified 14 PON2 tagSNPs that
captured all 19 PON2 variants in our sample, 12 of which were not in high LD with known PON1 and PON3 SNP
modifiers of PON activity. Stepwise regression analysis of PON activity, including the known modifiers, identified
five PON2 SNPs [rs6954345 (p.Ser311Cys), rs13306702, rs987539, rs11982486, and rs4729189; P = 0.005 to 2.1 × 10
-6]
that were significantly associated with PON activity. We found no association of PON2 SNPs with SLE risk but
modest associations were observed with lupus nephritis (rs11981433, rs17876205, rs17876183) and immunologic
disorder (rs11981433) in SLE patients (P = 0.013 to 0.042).
Conclusions: Our data indicate that PON2 genetic variants significantly affect variation in serum PON activity and
have modest effects on risk of lupus nephritis and SLE-related immunologic disorder.
Background
Systemic lupus erythematosus (SLE), a systemic autoim-
mune disease with high female predominance (female to
male ratio = 9:1) in reproductive years (15-44 years), is
characterized by a pronounced inflammation and the
production of a variety of autoantibodies against multi-
ple antigens. SLE pathogenesis is influenced by several
genes, hormones and environmental agents. Familial
aggregation and high heritability (up to 66%) suggest
that the genetic elements have strong influence on SLE
predisposition [1,2].
A prime cause of high mortality rate in SLE women is
attributed to an unusually high rate of premature coron-
ary artery disease (CAD) with risk of myocardial infarc-
tion 50 times higher than the general population [3].
The paraoxonase (PON) genes have received major
attention as antioxidants that attenuate oxidation of low
density lipoprotein (LDL), a key regulator in the patho-
genesis of atherosclerosis leading to several cardiovascu-
lar diseases [4]. Low serum paraoxonase (PON) activity
(using paraoxon as a substrate) is a significant risk fac-
tor for CAD [5,6]. Low PON activity is also associated
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[7,8]. PON activity is under genetic control and the var-
iants in the PON1 gene have strong influences on PON
activity variation [7,9].
PON2 is a positional candidate for SLE risk as the
entire PON locus comprising three genes (PON1, PON2
and PON3) on chromosome 7q21.3 lies close to a link-
age peak for SLE (LOD score of 2.40) in the same
region (7q21-22) [10,11]. All PON genes are antioxidants
and can hydrolyze a variety of substrates [4,12]. PON1
and PON3 a r em a i n l ye x p r e s s e di nt h el i v e ra n dt h e i r
protein products circulate in the blood as HDL-bound,
while PON2 is ubiquitously expressed in human tissues
and its product remains mostly intracellular as mem-
brane-bound [4]. PON2 gene spans nearly 30 kb on
chromosome 7 with 9 exons encoding two protein iso-
forms of 354 (NCBI Reference Sequence: NP_000296.2)
and 342 (NCBI Reference Sequence: NP_001018171.1)
amino acids [10]. Two common nonsynonymous PON2
coding variants have been reported to date [rs11545941
(p.Ala148Gly) and rs6954345 (p.Ser311Cys)] and the lat-
ter has been hypothesized to be a catalytic center for
the hydrolysis of oxidized lipids [13]. So far, the PON2
reports mainly examined these two coding polymorph-
isms, of which the rs6954345 (p.Ser311Cys) SNP was
found to be associated with several cardiovascular com-
plications [14-16] and renal dysfunction [17], whereas
the rs11545941 (p.Ala148Gly) SNP associated with
plasma lipoprotein levels in some studies [18]. Recently,
the PON2 protein was reported to degrade and inacti-
vate N-3-oxododecanoyl-homoserine lactone, the
quorum sensing signal of pathogenic bacteria [19] but
its exact physiologic or pathophysiologic role has yet to
be identified. PON2 protein shows highest lactonase
activity among all PON proteins and the rs6954345 (p.
Ser311Cys) SNP in recombinant PON2w a sr e c e n t l y
shown to cause altered glycosylation and impaired lacto-
nase activity [20].
Our previous reports with SLE datasets have identified
low PON activity as an independent risk factor for SLE
and our analysis of PON1 and PON3 SNPs revealed
some modest associations with lupus nephritis [7,21].
The PON1 and PON3 SNPs account for 30-40% of
serum PON activity variation in Caucasians [7,21].
Given that PON1-2-3 gene cluster resides close to a
linkage peak for SLE and our previous observations sug-
gesting a relationship between SLE and PON activity/
PON1-3 genetic variation, the purpose of this study was
to investigate the remaining member of the PON multi-
gene family, PON2. We genotyped and analyzed 19
highly informative PON2 SNPs selected from HapMap
and SeattleSNPs databases in a Caucasian SLE case-
control sample. To our knowledge, this is the first com-
prehensive association study of the PON2 variants with
risk of SLE, SLE-related clinical features and serum
PON activity.
Methods
Subjects
A total of 411 Caucasian women with SLE and 511 Cau-
casian healthy women with no apparent history of SLE
were studied. Peripheral blood samples were collected at
the baseline visit and used for genotyping and measure-
ment of serum PON activity (at the Pittsburgh site only)
as described previously [7].
Of 411 SLE cases, 344 belonged to the Pittsburgh
Lupus Registry and the rest (n = 67) to the Chicago
SOLVABLE study (Study of Lupus Vascular and Bone
Longterm Endpoints). All controls enrolled in our study
were geographically matched to the cases: 454 controls
were recruited from the Central Blood Bank of Pitts-
b u r g ha n dt h er e s t( n=5 7 )f r o mt h eC h i c a g oS O L V A -
BLE study. Demographic and clinical characteristics of
SLE patients and controls are presented in Table 1 and
described in detail elsewhere [22,23]. All SLE subjects
were adult women aged 18 years and older and met the
1982 [24] and 1997 [25] revised American College of
Rheumatology (ACR) classification criteria for SLE. The
subset of the ACR criteria that were included in associa-
tion analysis are shown in Table 1 [highly frequent (i.e.
Arthritis and ANA) or infrequent (i.e. Neurologic disor-
der) subphenotypes were not suitable for a meaningful
analysis given the size of our sample]. Also included in
Table 1 is the percentage of SLE cases who had experi-
enced one or more of physician-confirmed cardiac and
vascular events (myocardial infarction, coronary artery
bypass graft surgery, percutaneous transluminal coron-
ary angioplasty, angina pectoris, cardiac death, stroke,
transient ischemic attack, congestive heart failure, blood
clots, or vascular surgery) in a subset of the SLE sample
in which this data was available (n = 292). The mean ±
standard deviation (SD) age was 43.5 ± 11.4 years for
cases and 45.7 ± 12.9 years for controls. This study was
approved by the institutional review board and all sub-
jects gave written, informed consent.
Selection of PON2 SNPs and genotyping
We initially selected a total of twenty highly informative
PON2 SNPs [residing within PON2 or 1-kb flanking
regions and with ≥ 4% minor allele frequency (MAF)],
by using the LD and tagSNP information available for
Caucasians in the International HapMap http://www.
hapmap.org and SeattleSNPs http://pga.gs.washington.
edu/ databases (Figure 1). The tagSNP bins identified in
these 2 databases were not identical (likely due to the
sampling and methodological differences), thus we
selected at least one tagSNP from each bin defined in
these resources. One SNP (PON2/rs17876195) could not
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total of 19 successfully genotyped PON2 SNPs were
included in our analyses.
Genomic DNA was isolated from the buffy coat using
the QIAamp DNA kits (QIAGEN, Chatsworth, CA).
Ten PON2 SNPs (rs11982486, rs2286233, rs17876116,
rs11545941 (p.Ala148Gly), rs17876193, rs3735586,
rs10261470, rs9641164, rs13306702 and rs17876183)
were genotyped by Pyrosequencing using the PSQ HS
96 system (Biotage, Uppsala, Sweden) and the corre-
sponding PCR and sequencing primers were provided in
the Additional File 1, Table S1.
One of the PON2 coding SNPs, PON2/rs6954345 (p.
Ser311Cys), was genotyped by restriction fragment length
polymorphism (RFLP) analysis using the restriction
enzyme DdeI. The PCR primers (forward =
5’-AACAGGGCTTATTGATGATTGAGT-3’ and reverse
=5 ’-ACAGACCCATTGTTGGCATAA-3’)a m p l i f i e da
145 bp product containing the SNP of interest. DdeI
digestion of this product yielded a single fragment of 145
bp for GG genotype (CysCys), 2 fragments of 100 and 45
bp for CC genotype (SerSer), and 3 fragments of 145, 100
and 45 bp for the heterozygous CG genotype (SerCys).
The remaining eight PON2 SNPs (rs2299267,
rs12534274, rs987539, rs4729189, rs11981433, rs12704795,
rs1639 and rs17876205) were genotyped by TaqMan allelic
discrimination on an ABI 7900HT instrument (Applied
Biosystems, Foster City, CA) using the following SNP gen-
otyping assays: C___2630173_1_ for PON2/rs2299267,
C__31373224_10 for PON2/rs12534274, C___8952813_10
Table 1 Characteristics of the study population
Cases (n = 411) Controls (n = 511) Combined (n = 922)
Mean age 43.54 ± 11.36 45.68 ± 12.86 44.68 ± 12.22
Body mass index (kg/m
2) 26.90 ± 6.82 27.34 ± 6.59 27.14 ± 6.70
Current and/or Former Smoker (%) 37.84% 40.29% 39.23%
PON activity (in units/liter)* 613.88 ± 412.94 709.85 ± 496.39 671.44 ± 466.87
SLE manifestations (%)**
Skin rash (malar and/or discoid) 55% - -
Photosensitivity 63% - -
Oral ulcers 54% - -
Serositis (pleuritis or pericarditis) 44% - -
Renal involvement 30% - -
Hematologic involvement*** 54% - -
Immunologic involvement**** 72% - -
Cardiac and vascular events***** 33% - -
*Available only in a subset of the sample (291 cases and 436 controls).
**The subset of American College of Rheumatology (ACR) classification criteria for SLE that were included in association analysis.
***Hemolytic anemia or leukopenia (on two or more occasions) or lymphopenia (on two or more occasions) or thrombocytopenia.
****Anti-DNA antibody or anti-Sm antibody or positive finding of antiphospholipid antibodies.
*****Data available only in a subset of SLE patients (292 cases).
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Figure 1 Locations of the genotyped 19 PON2 SNPs. The exons are depicted as black bars (UTRs are highlighted as gray) and introns &
flanking regions as white bars.
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Page 3 of 9for PON2/rs987539, C__27922117_10 for PON2/
rs4729189, C___2630169_10 for PON2/rs11981433,
C__26570646_10 for PON2/rs12704795, C__11708890_10
for PON2/rs1639, and C__59001801_10 for PON2/
rs17876205.
Statistical analysis
Allele frequencies were calculated by allele counting
and all SNPs were tested for deviations from Hardy-
Weinberg Equilibrium (HWE) expectations. Haploview
http://www.broadinstitute.org/mpg/haploview was used
to assess the pairwise LD between all PON2 SNPs as
well as the two PON1 SNPs [PON1/rs662 (p.Gln192Arg)
and PON1/rs854560 (p.Leu55Met)] and the two PON3
SNPs (PON3/rs740264 and PON3/rs17884563) that we
previously reported to influence PON activity.
Data on PON activity was available only at the
Pittsburgh site and the raw measurements were square
root transformed to reduce non-normality. We con-
ducted combined (forward and reverse) stepwise and
multiple regression analyses to test for independent
association of PON activity with environmental covari-
ates [disease status, age, body mass index (BMI), smok-
i n g ][ 7 ]a sw e l la st h et w oPON1 SNPs [PON1/rs662
(p.Gln192Arg) and PON1/rs854560 (p.Leu55Met)], one
PON3 SNP (PON3/rs17884563) and 13 PON2 SNPs that
were in low LD. Allele effects were modeled as additive
for common SNPs and as dominant for relatively
uncommon variants. To determine whether additional,
unmeasured genetic variation in PON2 might also influ-
ence PON activity, we also evaluated the association of
PON2 haplotypes with PON activity.
Association of SLE status with PON2 SNPs was evalu-
ated using logistic regression and the recruitment site
(Pittsburgh or Chicago) and age (found to be significant
in stepwise regression analysis of potential covariates
examined, including the recruitment site, age, BMI and
smoking) were included as covariates in the model. SNP
effects were modeled as additive for common variants
and dominant for relatively uncommon ones. Within
SLE cases, the logistic regression analysis was performed
to test for association between PON2 SNPs and SLE-
related subphenotypes [skin involvement (malar rash
and/or discoid rash), lupus nephritis, photosensitivity,
oral ulcers, serositis, immunologic disorder and hemato-
logic involvement] using a dominant model and includ-
ing recruitment site and age as covariates.
All regression and haplotype analyses were per-
formed using the R Statistical Suite (R Foundation for
Statistical Computing, Vienna, Austria). Power analysis
was performed using the Quanto program http://hydra.
usc.edu/GxE.
Results
Pair-wise LD analysis of PON2 SNPs and relevant PON1
and PON3 SNPs
For all 19 PON2 SNPs, the observed minor allele fre-
quencies (MAFs) in our control sample were similar to
those reported in the HapMap database for Caucasians.
The observed genotype frequencies of all PON2 SNPs
were in accordance with HWE. Pairwise LD analyses
revealed similar patterns in cases and controls, hence
LD was computed by combining these two groups
(Figure 2). Significant correlations (r
2 ≥ 0.7) were found
between five PON2 SNP pairs [PON2/rs6954345
(p.Ser311Cys) & rs11545941 (p.Ala148Gly), r
2 = 0.81)],
[PON2/rs6954345 (p.Ser311Cys) & rs12534274, r
2 =
0.72], [PON2/rs6954345 (p.Ser311Cys) & rs3735586, r
2
= 0.92], [rs1639 & rs9641164; r
2 =0 . 8 7 ]a n d
[rs11981433 & rs12704795; r
2 = 0.98]. Hence, one of the
SNPs from each of these 5 highly correlated SNP pairs
[rs11545941 (p.Ala148Gly), rs12534274, rs3735586,
rs1639, and rs12704795] were excluded from subsequent
analyses. Although all 19 PON2 SNPs were reported as
tagSNPs in at least one of the two publicly available
databases using different r
2 cutoffs (HapMap and Seat-
tleSNPs), a total of 14 tagSNP bins were identified in
our sample using an r
2 cutoff of 0.7.
Because PON1, PON2 and PON3 genes lie adjacent to
each other and PON1 and PON3 variants are known
modifiers of PON activity, we also assessed LD between
the PON2 variants and the four PON1 and PON3 SNPs
that were previously found to be associated with PON
activity (Figure 2). Significant correlations (r
2 ≥ 0.7)
were observed between PON2/rs6954345 (p.Ser311Cys)
and PON3/rs740264 (r
2 = 0.77) and between PON2/
rs17876193 and PON3/rs17884563 (r
2 =0 . 8 1 ) .F r o m
the first correlated SNP pair, PON2/rs6954345 (p.
Ser311Cys) was included in subsequent analysis for
PON activity (regression and haplotype) since this SNP
had also tagged three other PON2 SNPs [rs11545941 (p.
Ala148Gly), rs12534274 & rs3735586]. From the second
correlated SNP pair, PON3/rs17884563 was included in
subsequent analysis of PON activity.
PON2 tagSNPs and serum PON activity
Table 2 shows the P and R
2 values from stepwise linear
regression analysis of PON activity with PON2 tagSNPs
along with the significant PON activity modifiers from
PON1 [7] and PON3 [21] genes and possible environ-
mental covariates (disease status, age, BMI, and smoking
status). In addition to previously reported effects of dis-
ease status, age, and the PON1 and PON3 SNPs, we iden-
tified associations with 5 PON2 SNPs: rs13306702 (P =
0.005), PON2/rs6954345 (p.Ser311Cys) (P =2 . 1×1 0
-6),
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-5), rs11982486 (P =7 . 0×1 0
-4),
and rs4729189 (P = 0.003). The same environmental cov-
ariates and SNPs were significant when all covariates and
SNPs were entered in the model simultaneously. The
beta values listed in Table 2 represent the effect of the
m i n o ra l l e l eo fe a c ho f5PON2 SNPs on PON activity
(square root transformed). PON activity increased with
the presence of minor alleles of PON2/rs6954345 (p.
Ser311Cys) and PON2/rs13306702 SNPs, and decreased
with the presence of the minor alleles of the remaining 3
significant PON2 SNPs. Altogether, these 5 PON2 SNPs
explained 3.4% of the variation in PON activity.
To assess whether unmeasured variants might influ-
ence PON activity, we also performed haplotype analysis
for PON activity (Table 3). Because of the strong effects
of PON1 and PON3 SNPs on PON activity, we performed
haplotype analysis after adjusting for disease status, age,
BMI, smoking, PON1/rs662 (p.Gln192Arg), PON1/
rs854560 (p.Leu55Met), and PON3/rs17884563. Only
one haplotype, Hap 6, was significantly associated with
increased PON activity (P =6 . 1×1 0
-5)c o m p a r e dt ot h e
most common haplotype (Hap Base). This haplotype
contained the minor allele for PON2/rs6954345 (p.
Ser311Cys) that is the most significant of the PON2 var-
iants. Therefore, this result is consistent with our
Figure 2 Pairwise linkage disequilibrium plot of PON1/rs662 (p.Gln192Arg), PON1/rs854560 (p.Leu55Met), PON3/rs740264, PON3/
rs17884563, and 19 PON2 SNPs in the combined sample (cases & controls) showing r
2 (×100) values.
Table 2 Significant results obtained from stepwise linear
regression analysis of serum PON activity (square root
transformed) with SLE disease status, age, BMI, smoking,
PON1/rs662 (p.Gln192Arg), PON1/rs854560 (p.Leu55Met)
and PON3/rs17884563 SNPs and 13 PON2 tagSNPs
FACTOR MAF Beta P R
2
disease -2.22 3.8 × 10
-8 0.015
age 0.04 0.013 0.003
PON1/rs662 (p.Gln192Arg) 0.280 10.54 <2.0 × 10
-16 0.392
PON1/rs854560 (p.Leu55Met) 0.358 -1.96 1.1 × 10
-8 0.017
PON3/rs17884563 0.092 -1.03 0.082 0.001
PON2/rs13306702 0.017 3.87 0.005 0.004
PON2/rs6954345 (p.Ser311Cys) 0.233 2.22 2.1 × 10
-6 0.011
PON2/rs987539 0.454 -3.64 3.4 × 10
-5 0.009
PON2/rs11982486 0.330 -2.84 7.0 × 10
-4 0.006
PON2/rs4729189 0.223 -2.61 0.003 0.004
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cates that no specific haplotype influences PON activity
independent of the analyzed PON2 genotypes.
PON2 tagSNPs and SLE risk
We examined the relation of 14 PON2 tagSNPs with
SLE risk through single-site and haplotype analyses.
Four PON2 tagSNPs had less than 5 individuals who
were homozygous for the minor allelle: PON2/
rs13306702, PON2/rs17876116, PON2/rs17876183 and
PON2/rs17876205. For these SNPs, the rare homozy-
gotes were combined with the heterozygote individuals
for the association analysis with SLE risk (dominant
model). The remaining SNPs (MAF range: ~10-45%)
were analyzed under the additive model for which we
had 80% power to detect a minimum OR of ~1.5-1.3 at
the 5% significance level. In single-site analysis, the gen-
otype frequencies of all PON2 tagSNPs were comparable
between cases and controls. Like single-site, no signifi-
cant association was found with the 14-site PON2 hap-
lotype analysis (data not shown).
PON2 tagSNPs and SLE-related clinical manifestations
In addition to SLE risk, we examined the association of
14 PON2 tagSNPs with seven SLE-related subphenotypes
within the SLE sample, by stratifying the SLE cases for
the presence and absence of the subphenotype of interest
a n du s i n gad o m i n a n tm o d e l .T h r e ePON2 tagSNPs
(rs11981433, rs17876183, and rs17876205) showed
modest association with lupus nephritis (age and recruit-
ment site adjusted p-values ranging between 0.013-
0.032). The genotype distributions of these SNPs in SLE
cases with/without nephritis and the age and recruitment
site adjusted ORs were as follows; for rs11981433 TT:
43.80%/33.68% & TC+CC: 56.20%/66.32% (OR: 0.61, 95%
CI: 0.39-0.96, P = 0.032), for rs17876183 GG: 93.50%/
98.25% & GA+AA: 6.50%/1.75% (OR: 4.63, 95% CI: 1.37-
15.59, P = 0.013), and for rs17876205 GG: 93.50%/
98.24% & GC+CC: 6.50%/1.76% (OR: 4.09, 95% CI: 1.26-
13.24, P = 0.019). One of these SNPs, rs11981433,
showed also modest association with immunologic disor-
der in the same direction as observed for lupus nephritis
(TT: 39.66%/29.31% & TC+CC: 60.34%/70.69%, adjusted
OR: 0.62, 95% CI: 0.39-0.98, P = 0.042). No other signifi-
cant associations were observed between PON2 tagSNPs
and SLE-related subphenotypes evaluated in this study.
Discussion
Inter-individual variation in serum PON activity is
under strong genetic influence and PON1 genetic var-
iants appear to be the main contributors [7,9]. We have
previously shown that in addition to PON1 SNPs, the
PON3 SNPs also influence serum PON activity, although
at a lesser degree [7,21]. Altogether PON1/rs662 (p.
Gln192Arg), PON1/rs854560 (p.Leu55Met), PON3/
rs740264 and PON3/rs17884563 SNPs account for more
than 40% of variation in serum PON activity among
Caucasians [7,21]. Since the impact of PON2 SNPs on
Table 3 Haplotype analysis of 13 PON2 tagSNPs in relation to PON activity adjusted for disease status, age, BMI,
smoking, PON1/rs662 (p.Gln192Arg), PON1/rs854560 (p.Leu55Met), and PON3/rs17884563
Haplotypes
Hap 1 Hap 2 Hap 3 Hap 4 Hap 5 Hap 6 Hap Rare Hap Base
PON2/rs17876205 GGGGG G * G
PON2/rs13306702 GGGGG G * G
PON2/rs6954345 (p.Ser311Cys) CCCCC G * C
PON2/rs9641164 AAATT A * A
PON2/rs987539 CCCTT T * C
PON2/rs17876116 GGGGG G * G
PON2/rs2286233 ATTAA A * A
PON2/rs11981433 CTTTT T * C
PON2/rs11982486 TTTTT T * C
PON2/rs4729189 TTTAA A * A
PON2/rs10261470 AAGGG G * G
PON2/rs2299267 AAAAG A * A
PON2/rs17876183 GGGGG G * G
Haplotype Frequency 0.073 0.051 0.052 0.052 0.096 0.192 0.161 0.323
Coefficient 0.21 1.14 0.31 0.47 -0.57 1.66 0.06
Standard Error 0.56 0.72 0.68 0.70 0.80 0.41 0.44
T statistic 0.38 1.59 0.46 0.67 -0.72 4.04 0.14
P 0.705 0.113 0.643 0.506 0.475 6.1 × 10
-5 0.890
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date, we examined the role of PON2 tagSNPs in regula-
tion of serum PON activity while taking also into
account the effects of the SNPs in PON1 and PON3
genes that lie in close vicinity of PON2.
We found significant associations of one coding
and four non-coding PON2 tagSNPs, [rs6954345 (p.
Ser311Cys), rs13306702, rs987539, rs11982486, and
rs4729189 with p-values ranging from 0.005 to 2.1 × 10
-6]
with PON activity, after incorporating effects of relevant
PON1 and PON3 SNPs as well as environmental covari-
ates. The overall contribution of PON2 genetic variation
on PON activity was 3.4%. A similar association of the
PON2/rs6954345 (p.Ser311Cys) SNP with serum PON
activity in the same direction (minor allele associated with
increased PON activity) has also been reported by Mack-
ness et al. (2000) in type II diabetic individuals [26].
Although PON2/rs6954345 (p.Ser311Cys) SNP is highly
correlated with PON3/rs740264 SNP which is a known
modifier of PON activity (r
2=0.77; see the second para-
graph in LD analysis results), the observation of 4 addi-
tional independently and highly significantly associated
PON2 tagSNPs supports a possible independent effect of
PON2 genetic variation on PON activity.
The lower contribution of PON2 on PON activity as
compared to PON1 and PON3 is likely due to the fact
that unlike PON1 and PON3 proteins that are bound
to circulating HDL in the blood, PON2 protein is
believed to be predominantly intracellular and mem-
brane bound [27-30]. The observed effect on PON
activity may be related to a low level secretion of
PON2 enzyme into blood [27] and/or the presence of
a low-abundant secreted PON2 isoform. Ng et al.
(2001) [27] failed to detect PON2 protein secretion by
Western analysis despite the presence of a “putative
consensus signal sequence” in PON2 N-terminal region
(similar to that in PON1 and PON3), therefore they
argued that the protein could either be subject to
rapid degradation following its secretion or secreted at
a very low level. Although most studies mainly focused
on two PON2 isoforms [29,31], Mochizuki et al. (1998)
[32] reported that alternative splicing of PON2 tran-
script results in several PON2 splice forms. Neverthe-
less, our results indicate only a small effect of PON2
variation on serum PON activity and confirms that the
circulatory HDL-bound PON1 is the major modulator.
Lack of complete knowledge regarding the natural sub-
strate for PON2 enzyme is a major limiting factor in
evaluating the role of PON2 genetic variation in PON2
enzymatic activities.
Although several studies linked PON2 variants to var-
ious diseases like amyotrophic lateral sclerosis [33,34],
Alzheimer’s disease [35], CHD [14-16], and metabolic
traits [18] with controversial findings [36], there is no
published study that links PON2 with SLE risk. Regard-
less of the association observed between PON2 variants
and PON activity, we did not find any major contribu-
tion of PON2 genetic variation to overall SLE risk
neither in single-site or haplotype analyses. This is con-
sistent with our prior observations regarding the relation
between PON1 and PON3 SNPs and SLE risk [7,21].
Lupus nephritis is a major cause of mortality in SLE
patients [1]. Some studies reported associations of
PON2 genetic variation with renal dysfunction or
nephropathy [17,37]. Our group previously reported
modest associations of three PON1 promoter SNPs with
lupus nephritis in Caucasian SLE patients [7]. Similarly,
we observed modest associations of PON2 SNPs with
lupus nephritis in Caucasian SLE cases (rs11981433,
rs17876183 and 17876205 with covariate-adjusted
p-values ranging between 0.013-0.032). Our pairwise LD
analysis of the nephritis-associated three PON1 promo-
ter SNPs [7] (rs705379, rs705381 and rs854573) and
three PON2 SNPs did not reveal high correlations
between these SNPs (data not shown). A large prospec-
tive study [17] comprising 3,374 diabetic subjects evalu-
ated PON2 variations with indices of renal dysfunction
and reported the association of PON2/rs6954345 (p.-
Ser311Cys) and rs12704795 SNPs with renal dysfunc-
tion. Although no association was observed with PON2/
rs6954345 (p.Ser311Cys) SNP and lupus nephritis in our
study, significant association was found with PON2/
rs11981433 SNP that is highly correlated with PON2/
rs12704795 SNP (r
2 = 0.98). Our results also revealed a
modest association of PON2/rs11981433 SNP with
immunologic disorder (adjusted P = 0.042). Although
the associations observed with SLE subphenotypes were
not strong enough to survive correction for multiple
testing, the association of rs11981433 SNP with more
than one SLE subphenotype in the same direction (pro-
tective) would argue in favor of its possible genuine
effect on SLE-related clinical features.
Conclusions
In summary, our results suggest that PON2 genetic var-
iation is significantly and independently associated with
variation in serum PON activity (after incorporating
effects of age, SLE status, relevant PON1 and PON3 var-
iation), although to a much lesser extent than PON1.
We found no obvious association between PON2
tagSNPs and SLE risk, however, we observed few mod-
est associations with lupus nephritis and SLE-related
immunological disorder which await replication in larger
independent samples. A comprehensive resequencing
and association analysis of PON gene cluster may help
to better understand extent to which this locus contri-
butes to the regulation of PON activity and to the risk
of SLE-related clinical features.
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